Clinical TrialLevosimendan Improves Renal Function in Patients With Advanced Chronic Heart Failure Awaiting Cardiac Transplantation
Section snippets
Patient Population
In a prospective trial, we enrolled 40 consecutive patients with advanced chronic heart failure who were referred for cardiac transplantation listing at Advanced Heart Failure and Transplantation Program, Ljubljana University Medical Center. All patients were NYHA Class III or IV class heart failure for at least 3 months before referral, and were treated with optimal medical therapy at maximally tolerated doses according to the latest guidelines.8 Before listing, all patients were screened
Patient Characteristics
Baseline patient characteristics are presented in Table 1. The 2 groups did not differ in age, heart failure etiology, heart rate, QTc interval, sodium, left ventricular ejection fraction, or plasma brain natriuretic peptide (BNP) levels. All of the patients survived the follow-up period, and none underwent heart transplantation or implantation of a left ventricular assist device. After 3 months, we found an improvement in left ventricular ejection fraction in the LS Group, but not in Controls (
Discussion
This is the first study to date evaluating the long-term effects of levosimendan on renal function in patients with advanced heart failure listed for heart transplantation. In these patients, a 24-hour levosimendan infusion was associated with a significant improvement in renal function 1 month after therapy, with its effect persisting up to 3 months. This suggests that levosimendan may exert a sustained beneficial effect on renal function in advanced heart failure.
In patients with severe heart
Conclusions
The results of this study suggest that levosimendan exerts beneficial effects on renal function in patients with advanced chronic heart failure. Although the effects are modest, they appear to persist up to 3 months after the infusion. Further studies are needed to better define the underlying mechanisms and to determine whether or not the levosimendan-related improvement in renal function offers a survival benefit in this patient cohort.
Acknowledgments
The authors would like to thank Andreja Briski for coordinating the study and for her dedicated assistance throughout the study period.
References (21)
- et al.
Pre-operative renal function predicts development of chronic renal insufficiency after orthotopic heart transplantation
J Heart Lung Transplant
(2002) - et al.
Peri-operative renal function and outcome after orthotopic heart transplantation
J Heart Lung Transplant
(2006) - et al.
Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised, double-blind trial
Lancet
(2002) - et al.
The prognostic importance of different definitions of WRF in congestive heart failure
J Card Fail
(2002) - et al.
Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure
Am J Cardiol
(2004) - et al.
Race and renal impairment in heart failure: Mortality in black versus whites
Circulation
(2005) - et al.
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure
Circulation
(2006) - et al.
Renal function, neurohormonal activation, and survival in patients with chronic heart failure
Circulation
(2000) - et al.
Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE
Eur J Heart Fail
(2006) - et al.
Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology
Eur Heart J
(2005)
Cited by (77)
Heart–Kidney Interactions in Cardiorenal Syndrome Type 1
2018, Advances in Chronic Kidney DiseaseCitation Excerpt :Currently, no specific treatment exists to prevent CRS-1, and the best clinical approach consists in optimization of predisposing risk factors, hemodynamic derangement, therapies to improve congestion status, and neurohormonal activity modulation. Recent trials including inotropes (milrinone, levosimendan, and dopamine),63-65 BNP recombinant (nesiritide),66,67 antagonist receptors of vasopressin,26 and adenosine antagonist62,68 in the setting of ADHF have not been promising. Focusing on the effectiveness of treatment in reducing congestion and dyspnea has been widely shown to be insufficient because many patients may still worsen clinically, despite a progressive relief of signs and symptoms after admission.
Inotropes and cardiorenal syndrome in acute heart failure – A retrospective comparative analysis
2017, Revista Portuguesa de CardiologiaCitation Excerpt :Unfortunately, the clinical management of CRS is largely empirical and many drugs traditionally used to treat HF (diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone antagonists) may result in renal dysfunction due to their serious side effects, especially following inappropriate or excessive use.19,20 Levosimendan is a positive inotropic drug with vasodilatory properties that has been assessed in several clinical studies in patients with AHF, which demonstrated improvements in renal hemodynamics and laboratory markers of renal function.13,14,21–24 However, there are few studies comparing the renoprotective profile of levosimendan with that of dobutamine in patients with AHF.13,14
Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper
2016, International Journal of CardiologyThe role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion
2016, International Journal of CardiologyCardiorenal Interactions
2016, Heart Failure ClinicsMultiorgan Transplantation: Heart-Kidney
2023, Textbook of Transplantation and Mechanical Support for End-Stage Heart and Lung Disease